It has been a year since Mary Till joined Finnegan as of counsel. To reflect on her year, Mary spoke with Managing Intellectual Property and shared how she is applying her nearly 20 years of experience at the United States Patent and Trademark Office to her role and how it has shaped her practice.
Mary said she has helped many pharma and biotech clients with strategic analysis of their portfolios for the purpose of obtaining a Patent Term Extension (PTE) – an area she worked on at the agency. Patent owners can obtain a PTE to make up for time lost while awaiting regulatory review of their products. Till was involved in around 400 or 500 PTE cases while at the agency, she said.
“My knowledge and expertise in that area make it something that people seek me out for when they have questions,” Mary said. “If an application gets stuck somewhere and isn’t going along the path it’s supposed to be, I pretty much know how to fix that.”
Read “How Former USPTO Advisor Is Using Her Expertise at Finnegan”
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Press Release
BMW Obtains Preliminary Injunction Against Zync; Federal Court Orders Zync to Halt ITC Trade Secret
June 23, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Commentary
U.S. Judge Rules Forum-Selection Clause Bars Zync from Pursuing ITC Trade Secret Case
June 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.